Recent

% | $
Quotes you view appear here for quick access.

ADVENTRX Pharmaceuticals, Inc. Message Board

  • rory1_2000 rory1_2000 Dec 23, 2012 10:53 AM Flag

    Reverse Splits:

    Focus on fundamentals
    ...For a company's stock to trade low enough that it'll even consider a reverse split, it typically has to endure a terrible period of financial results. The split itself doesn't solve the operational problems a company faces, so companies that can't find a way to recover simply fail. The few that do find permanent solutions to their problems may have spectacular runs, but from an overall return perspective, they simply can't outweigh the vast majority of firms that fail.

    Stocks that choose to undertake reverse splits brand themselves with a red flag. Given their reputation as wealth-killers, reverse splits simply drive away many investors from ever considering a given stock. If that aversion proves to be irrational -- that is, if investors abandon the stock for dead, even after its business prospects revive -- then it can be potentially quite lucrative for those who keep their eyes open to the opportunities it presents.

    All other things being equal, though, companies that get themselves into a position where they need a reverse split have a lot against them from the start. Except in the most extraordinary cases, therefore, investors may be smarter to seek better investments elsewhere.

    `
    From Motley Fool Info on Reverse Split Stats.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hello rory1_2000,

      July 12, 2011 - $3.91
      July 14, 2011 - $3.52
      July 29, 2011 - $2.95
      August 5, 2011 - $2.46

      August 10, 2011 - $1.06
      September 30, 2011 - $0.92
      December 30, 2011 - $0.59

      December 31, 2012 - $0.57
      ------

      clinicaltrials.gov
      ClinicalTrials.gov Identifier: NCT01737814
      This study is not yet open for participant recruitment.
      Verified November 2012 by Adventrx Pharmaceuticals
      Sponsor: Adventrx Pharmaceuticals
      First received: November 27, 2012
      Last updated: November 29, 2012
      Last verified: November 2012

      The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.

      Estimated Enrollment: 388
      Study Start Date: December 2012
      Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)

      ClinicalTrials.gov processed this record on December 30, 2012

    • wwzg@sbcglobal.net wwzg Dec 24, 2012 5:43 PM Flag

      The long holders here should welcome ANX going to .25 cents for they will be able to get a ton of dung for 1/2 the price. Now if any long holder is against this thought and is in panic mode that alone is proof that they are basically a pumper and will unload on ANY new sucker that is conned into buying this shell game stock .....

      Sentiment: Strong Sell

      • 1 Reply to wwzg
      • But the long holders say you mean old bashers are going to make them cry. Why? I think they are very glad to own this ANX stock. They keep saying its makin them money. i don't really get that because it has only been losing money. Except for that telecastrated guy. He is a swing trader I read. Hes prbably getting real rich. He's cringeworthy i bet you.

    • July 12, 2011 - $3.91
      July 14, 2011 - $3.52
      July 27, 2011 - $2.94
      August 5, 2011 - $2.46
      August 10, 2011 - $1.06
      December 30, 2011 - $0.59
      December 21, 2012 - $0.58

      Adventrx Pharmaceuticals, Inc.
      10-Q
      11/05/2012
      (21)
      (22)
      "Although we anticipate that our cash, cash equivalents and short-term investments as of September 30, 2012 will be sufficient to fund our currently planned level of operations for at least the next 12 months, we expect to incur significant and increasing losses for the next several years as we advance our product candidates through clinical studies and other development activities and seek regulatory approval to commercialize such product candidates. In addition, we may seek to expand our product pipeline through acquisition of additional product candidates and/or technologies. We will need additional capital to support our planned operating activities. For the foreseeable future, we likely will seek to fund our operations through public or private equity and/or debt financings and/or strategic alliances, including licensing transactions. Even though we were able to raise significant funds in the past through equity financings, the conditions of and our access to capital markets are highly variable and adequate additional financing may not be available to us in the future on acceptable terms or on a timely basis or at all. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and ability to pursue our business strategy."

      • 1 Reply to unifort37
      • True indeed gentlemen: ANX's last 1:25 stock split, in order to avert their "failure to raise capital as and when needed (which) would have a material adverse effect on our financial condition and ability to pursue our business strategy", is a testimony to their own parenthetical statement (Which Unifort so aptly provided).

        "BUSINESS STRATEGY"???? LOL!!!
        More like business tragedy....

        "Fanaticism consists in redoubling your efforts when you have forgotten your aim."
        ~George Santayana

    • A company with so much cash that has to rev split like anx,,is just taking people for all theyre worth.. Anx has 2 rev splits since 1995. following the gnta path and people here will be broke as a joke!

 
ANX
0.0000(0.00%)